MRK ▲ +0.0% - Merck & Co., Inc. $MRK Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan Merck announced that Japan has approved KEYTRUDA QLEX, a subcutaneous formulation of its blockbuster cancer immunotherapy pembrolizumab, for all indications where the standard intravenous version is approved in the country. The subcutaneous option offers patients a more convenient alternative to IV administration, potentially expanding the drug's utility and patient accessibility in a major market. MRK was flat on the day. 21-SEP-2026 06:45 AM ET